

REMARKS

The Examiner requested that Applicants elect one of eight groups. Applicants hereby elect Group I. Applicants furthermore, elect the compound exemplified

CP-775356-01: (+/-)-3-[1-[2-(2-Methoxy-phenyl)-ethyl]-trans-3,4-dimethyl-piperidin-4-yl]-Benzamide

Furthermore, traverse the restriction to the extent that the Examiner segregated the method of treatment claims from the corresponding compound claims. In particular, Applicants request that the Examiner consider grouping Groups I and IV. Alternatively, Applicants request that Group IV be rejoined upon a determination of patentability of Group I.

CONCLUSION

Applicants respectfully request entry of the amendments herein above, and an early and favorable allowance.

Respectfully submitted,

Date: August 17, 2006  
Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-4288

/ Martha G. Munchhof /  
Martha G. Munchhof  
Attorney for Applicant(s)  
Reg. No. 47,811